MML Investors Services LLC Purchases Shares of 684 United Therapeutics Co. (NASDAQ:UTHR)

MML Investors Services LLC acquired a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 684 shares of the biotechnology company’s stock, valued at approximately $245,000.

Several other large investors have also modified their holdings of UTHR. LSV Asset Management lifted its holdings in shares of United Therapeutics by 82.5% during the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after purchasing an additional 436,851 shares during the last quarter. World Investment Advisors LLC purchased a new stake in United Therapeutics during the third quarter valued at about $139,206,000. FMR LLC boosted its holdings in shares of United Therapeutics by 41.1% in the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after buying an additional 314,004 shares during the period. Assetmark Inc. increased its position in shares of United Therapeutics by 56.9% in the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after acquiring an additional 152,249 shares in the last quarter. Finally, Pacer Advisors Inc. increased its position in shares of United Therapeutics by 19.6% in the second quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock worth $178,972,000 after acquiring an additional 92,240 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CFO James Edgemond sold 7,794 shares of United Therapeutics stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $355.54, for a total value of $2,771,078.76. Following the transaction, the chief financial officer now directly owns 5,344 shares in the company, valued at approximately $1,900,005.76. The trade was a 59.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Louis W. Sullivan sold 26,209 shares of the business’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the transaction, the director now directly owns 5,051 shares of the company’s stock, valued at $1,885,134.22. This represents a 83.84 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 137,753 shares of company stock worth $51,787,157. 11.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on UTHR shares. LADENBURG THALM/SH SH raised their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. The Goldman Sachs Group raised their target price on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. Oppenheimer upped their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Argus raised their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Finally, HC Wainwright upped their target price on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $370.86.

United Therapeutics Trading Down 0.8 %

United Therapeutics stock opened at $360.87 on Thursday. The company has a market capitalization of $16.11 billion, a P/E ratio of 15.85, a P/E/G ratio of 1.05 and a beta of 0.55. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82. The firm’s fifty day simple moving average is $371.01 and its 200-day simple moving average is $347.25.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.38 earnings per share. On average, equities research analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.